Invasive fungal infections in patients with systemic lupus erythematosus

J Rheumatol. 2012 Sep;39(9):1814-8. doi: 10.3899/jrheum.111498. Epub 2012 Jun 15.

Abstract

Objective: Invasive fungal infections (IFI) are catastrophic diseases associated with a high mortality. Relatively few cases of IFI have been described in systemic lupus erythematosus (SLE) and their related factors have not been completely explored. We evaluated factors associated with IFI in patients with SLE.

Methods: All patients with both IFI and SLE admitted to our hospital in the last 7 years were evaluated and each was compared with 5 hospitalized patients with SLE (controls). Demographic factors, duration of SLE, and treatment in the previous month were compared.

Results: Sixty patients with SLE were evaluated (10 with IFI and 50 controls). Median age was 29 years. High C-reactive protein levels were associated with IFI, along with other factors such as high disease activity, mechanical ventilation, treatment with antibiotics, hemodialysis, high doses of glucocorticoids (GC), and treatment with mycophenolate mofetil. Mortality was 4 times more frequent in patients with IFI than in SLE patients without the deep fungal infection.

Conclusion: IFI is a rare infection observed in patients with rheumatic diseases. We describe factors associated with IFI in patients with SLE. IFI is associated with elevated morbidity and mortality. Early diagnosis and treatment are desirable.

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • C-Reactive Protein
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / microbiology
  • Lupus Erythematosus, Systemic / mortality
  • Male
  • Middle Aged
  • Mycoses / complications*
  • Mycoses / drug therapy
  • Mycoses / mortality
  • Risk Factors
  • Severity of Illness Index

Substances

  • Antifungal Agents
  • Glucocorticoids
  • C-Reactive Protein